At the time of writing, Atea Pharmaceuticals Inc [AVIR] stock is trading at $3.10, up 5.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVIR shares have gain 2.65% over the last week, with a monthly amount drifted -6.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Atea Pharmaceuticals Inc [NASDAQ: AVIR] stock has seen the most recent analyst activity on August 13, 2024, when Morgan Stanley upgraded its rating to a Equal-Weight and also boosted its price target to $6.88 from $2. Previously, JP Morgan downgraded its rating to Underweight on August 10, 2023. On January 06, 2022, downgrade downgraded it’s rating to Underweight and revised its price target to $7 on the stock. SVB Leerink downgraded its rating to a Mkt Perform. JP Morgan downgraded its rating to a Neutral and reduced its price target to $16 on October 20, 2021. Morgan Stanley downgraded its rating to Equal-Weight for this stock on October 05, 2021, but kept the price target unchanged to $55. In a note dated November 25, 2020, Evercore ISI initiated an Outperform rating.
For the past year, the stock price of Atea Pharmaceuticals Inc fluctuated between $2.75 and $4.60. Currently, Wall Street analysts expect the stock to reach $6.88 within the next 12 months. Atea Pharmaceuticals Inc [NASDAQ: AVIR] shares were valued at $3.10 at the most recent close of the market. An investor can expect a potential return of 121.94% based on the average AVIR price forecast.
Analyzing the AVIR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.35 and Total Capital is -0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.05 points at the first support level, and at 2.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.20, and for the 2nd resistance point, it is at 3.29.
Ratios To Look Out For
It is important to note that Atea Pharmaceuticals Inc [NASDAQ:AVIR] has a current ratio of 19.33. Also, the Quick Ratio is 19.33, while the Cash Ratio stands at 3.91.
Transactions by insiders
Recent insider trading involved BERGER FRANKLIN M, Director, that happened on Dec 10 ’24 when 0.36 million shares were sold. Lead Independent Director, Franklin Berger completed a deal on Dec 10 ’24 to buy 0.36 million shares. Meanwhile, President, CEO, and Chairman Sommadossi Jean-Pierre sold 33941.0 shares on Sep 17 ’24.
